DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5zc2lm/pharmapoint) has announced the addition of the "PharmaPoint: Irritable Bowel Syndrome - Japan Drug Forecast and Market Analysis to 2023" report to their offering.
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
The key growth drivers for the IBS market in Japan are the anticipated label expansion of Astellas' Irribow for the treatment of women with IBS-D, and the potential introduction of five additional therapies for IBS during the forecast period. Antidepressants represented the remaining 32% of the market. The anticipated label expansion of Irribow for treating women with IBS-D, and the potential introduction of five new therapies for IBS, is set to change the IBS market dynamics in Japan.
- Overview of Irritable Bowel Syndrome including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the Japan from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan Irritable Bowel Syndrome.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
5.2 Product Profiles - Major Brands, IBS-C
5.2.1 Amitiza (lubiprostone)
5.2.2 Linzess (linaclotide)
5.3 Product Profiles - Major Brands, IBS-D
5.3.1 Irribow (ramosetron)
5.4 Product Profiles - Major Brands, Other
5.5 Other Therapeutic Classes
6 Unmet Need and Opportunity
6.2 More Effective Pharmacotherapies
6.3 Therapies for the IBS-D Subtype
6.4 Therapies for the IBS-M Subtype
6.5 Therapies to Address Abdominal Pain and Bloating Symptoms
6.6 Improved Diagnosis Rate for IBS
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
7.3 Product Profiles - Late-Stage Pipeline, IBS-D
7.3.2 Ibodutant (MEN-15596)
7.4 Product Profiles - Late-Stage Pipeline, IBS-C
7.4.2 Tenapanor (AZD1722, RDX5791)
7.5 Other Drugs in Development for IBS
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/5zc2lm/pharmapoint